Table 2.

Response to imatinib mesylate therapy

Characteristic
No. (%)
Cytogenetic response; n = 256*  202 (79)  
    Complete†  162 (63)  
    Partial†  26 (10)  
    Minor   14 (5)  
Molecular response; n = 261  
    BCR-ABL/ABL less than 0.05%   82 (31)  
    Undetectable BCR-ABL   40 (15)  
Median follow-up, mos
 		 45
 
Characteristic
No. (%)
Cytogenetic response; n = 256*  202 (79)  
    Complete†  162 (63)  
    Partial†  26 (10)  
    Minor   14 (5)  
Molecular response; n = 261  
    BCR-ABL/ABL less than 0.05%   82 (31)  
    Undetectable BCR-ABL   40 (15)  
Median follow-up, mos
 		 45
 
*

Of the total 261 patients, 5 had 0% Ph-positive cells at the start of therapy and were not included in this analysis (1 of them had 20q- in 25% of metaphases).

†

These categories combined represent the major cytogenetic response (73%).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal